Disclosed herein are prokaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.
Barlow; Khan, British Journal of Pharmacology and Chemotherapy, 1959, vol. 14, p. 265,266
作者:Barlow、Khan
DOI:——
日期:——
GLENNON, RICHARD A.;TITELER, MILT;LYON, ROBERT A.;SLUSHER, R. M., J. MED. CHEM., 31,(1988) N 4, 867-870
作者:GLENNON, RICHARD A.、TITELER, MILT、LYON, ROBERT A.、SLUSHER, R. M.
DOI:——
日期:——
Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion
申请人:ELI LILLY AND COMPANY
公开号:EP0455510B1
公开(公告)日:1996-11-27
PROCESSES FOR THE PRODUCTION OF TRYPTAMINES
申请人:New Atlas Biotechnologies LLC
公开号:US20210108238A1
公开(公告)日:2021-04-15
Disclosed herein are prokaryotic and eukaryotic microbes, including
E. coli
and
S. cerevisiae
, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.